ONCY - オンコリティクス・バイオテック （Oncolytics Biotech Inc.）ONCYのニュース
Maxim Group maintains Oncolytics Biotech at ''buy'' with a price target of $5.00 2023/06/05 16:26:37 Investing.com
https://www.investing.com/news/pro/oncolytics-biotec-receives-investment-bank-analyst-rating-update-3098457
Oncolytics Biotech® Announces Updated Randomized Phase 2 Data from BRACELET-1 Metastatic Breast Cancer Trial that Show Pelareorep Driving Robust Increases in Progression-Free Survival and Confirmed Overall Response Rate 2023/06/05 12:00:05 FinancialNewsMedia
Pelareorep-paclitaxel combination reduced risk of disease progression by 71% (hazard ratio of 0.29) compared to paclitaxel monotherapy 37.5% confirmed overall response rate with pelareorep-paclitaxel vs. 13.3% with paclitaxel monotherapy 12-month progression-free survival rate of 32.8% for pelareorep-paclitaxel compared to 0% for paclitaxel monotherapy and 0% for pelareorep-paclitaxel-avelumab Oncolytics’ HR+/HER2- breast cancer program now phase 3-ready […] The post Oncolytics Biotech® Announces Updated Randomized Phase 2 Data from BRACELET-1 Metastatic Breast Cancer Trial that Show Pelareorep Driving Robust Increases in Progression-Free Survival and Confirmed Overall Response Rate appeared first on Financial News Media .
Oncolytics Biotech® Inc.: Oncolytics Biotech® Announces Updated Randomized Phase 2 Data from BRACELET-1 Metastatic Breast Cancer Trial that Show Pelareorep Driving Robust Increases in Progression-Free Survival and Confirmed Overall Response Rate 2023/06/05 11:06:00 Finanz Nachrichten
Pelareorep-paclitaxel combination reduced risk of disease progression by 71% (hazard ratio of 0.29) compared to paclitaxel monotherapy 37.5% confirmed overall response rate with pelareorep-paclita…
Oncolytics Biotech Reports Updated Data from BRACELET-1 Trial that Show Pelareorep Delivered Increases in Progression-Free Survival 2023/06/05 11:04:01 Investing.com
https://www.investing.com/news/assorted/oncolytics-biotech-reports-updated-data-from-bracelet1-trial-that-show-pelareorep-delivered-increases-in-progressionfree-survival-432SI-3098144
Oncolytics Biotech Announces Updated Randomized Phase 2 Data from BRACELET-1 Metastatic Breast Cancer Trial that Show Pelareorep Driving Robust Increases in Progression-Free Survival and Confirmed Overall Response Rate 2023/06/05 11:00:00 PR Newswire
Pelareorep-paclitaxel combination reduced risk of disease progression by 71% (hazard ratio of 0.29) compared to paclitaxel monotherapy 37.5% confirmed overall response rate with pelareorep-paclitaxel vs. 13.3% with paclitaxel monotherapy 12-month progression-free survival rate of 32.8%…
Oncolytics Biotech® Inc.: Oncolytics Biotech® Announces Upcoming Oral Presentation on Randomized BRACELET-1 Trial in HR+/HER2- Metastatic Breast Cancer at the ASCO Annual Meeting 2023/04/26 14:48:00 Finanz Nachrichten
Oral presentation on BRACELET-1 to take place on June 3, 2023 SAN DIEGO and CALGARY, AB, April 26, 2023 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced the accep…
Oncolytics Biotech® Inc.: Oncolytics Biotech® to Participate in a Panel Presentation at Canaccord Genuity''s Horizons in Oncology Virtual Conference 2023/04/12 11:30:00 Finanz Nachrichten
SAN DIEGO and CALGARY, AB, April 12, 2023 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that Chief Medical Officer Thomas Heineman, M.D., Ph.D., will participa…
Oncolytics Biotech® to Participate in a Panel Presentation at Canaccord Genuity''s Horizons in Oncology Virtual Conference 2023/04/12 11:23:00 Benzinga
SAN DIEGO and CALGARY, AB , April 12, 2023 /CNW/ -- Oncolytics Biotech ® Inc. (NASDAQ: ONCY ) (TSX: ONC ) today announced that Chief Medical Officer Thomas Heineman , M.D., Ph.D., will participate in the Viral Immunotherapy – Moving Forward panel at Canaccord Genuity''s Horizons in Oncology Virtual Conference, which is taking place virtually on April 20, 2023 . Additional details on the panel presentation can be found below. … Full story available on Benzinga.com
Oncolytics Biotech® Inc.: Oncolytics Biotech® to Host Conference Call to Discuss First Quarter Financial Results and Recent Operational Highlights 2023/04/12 11:06:00 Finanz Nachrichten
Conference call and webcast to take place on Friday, May 5, 2023, at 8:30 a.m. ET SAN DIEGO and CALGARY, AB, April 12, 2023 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today…
Oncolytics Biotech® Inc.: Oncolytics Biotech® Announces Filing and Mailing of the Management Information Circular in Connection with the Annual General Meeting of Shareholders 2023/04/12 10:48:00 Finanz Nachrichten
Your vote is important no matter how many votes you hold. Vote today Shareholders who have questions or need assistance with voting their shares should contact Oncolytics Biotech Inc.''s strategic …
Oncolytics Biotech Inc.: Oncolytics Biotech Announces Upcoming Presentations at the Society for Immunotherapy of Cancer 37th Annual Meeting 2022/10/05 12:10:00 Finanz Nachrichten
Interim results from the phase 1/2 GOBLET study''s pancreatic cancer cohort to be presented in a poster on November 11th and discussed during a key opinion leader webinar on November 14th at 10 a.m…
Oncolytics Biotech Inc.: Oncolytics Biotech Appoints Jonathan Rigby to its Board of Directors 2022/09/07 11:04:00 Finanz Nachrichten
Mr. Rigby is the Group Chief Executive Officer of Revolo Biotherapeutics and has three decades of experience in the pharmaceutical and biotechnology industries SAN DIEGO and CALGARY, AB, Sept. 7, …
RBC Capital Reiterates Outperform Rating on Oncolytics Biotech 2022/08/22 16:48:02 Investing.com
https://www.investing.com/news/pro/rbc-capital-reiterates-outperform-rating-on-oncolytics-biotech-432SI-2877592
Oncolytics Biotech Inc. (ONCY) CEO Matthew Coffey on Q2 2022 Results - Earnings Call Transcript 2022/08/11 20:21:09 Seeking Alpha
Oncolytics Biotech Inc. (NASDAQ:NASDAQ:ONCY) Q2 2022 Results Conference Call August 11, 2022 08:30 AM ET Company Participants Jon Patton - Director of Investor Relations and Communications…
Oncolytics Biotech Inc.: Oncolytics Biotech Reports Second Quarter 2022 Financial Results and Recent Operational Highlights 2022/08/11 11:04:00 Finanz Nachrichten
Phase 2 BRACELET-1 trial fully enrolled and advancing towards a randomized data readout that is expected to inform the design of a registrational study in HR+/HER2- breast cancer Achieved success …